ORIC Pharmaceuticals Raises $264M, Records 55% PSA50 and 80% ORR in Phase 1b
ORIC Pharmaceuticals closed 2025 with $392.3M in cash, cash equivalents and investments after raising $264M from specialist funds, extending runway into H2 2028. Phase 1b data showed 55% PSA50 responses in mCRPC and 67–80% ORR plus 100% intracranial ORR in EGFR exon 20 and PACC NSCLC, with RP2Ds selected.
1. Clinical Data Highlights
ORIC reported Phase 1b rinzimetostat results in metastatic castration-resistant prostate cancer demonstrating 55% of patients achieved PSA50 and 20% achieved PSA90, with 76% achieving >50% ctDNA reduction and 59% ctDNA clearance. Enozertinib data in NSCLC patients with EGFR exon 20 and PACC mutations showed 67% ORR and 80% ORR in first-line cohorts, plus 100% intracranial ORR in patients with measurable CNS disease.
2. Financial Results and Cash Runway
As of December 31, 2025, ORIC held $392.3 million in cash, cash equivalents and investments, bolstered by $124.4 million from a private placement and $117.6 million from ATM proceeds. A subsequent $20.0 million ATM raise increases proforma cash to $412.3 million, funding operations into the second half of 2028; Q4 R&D expenses declined to $25.9 million from $32.0 million year-earlier, with full-year R&D spending at $109.8 million.
3. Operational Updates and Milestones
The firm selected provisional RP2Ds for rinzimetostat in combination with darolutamide and apalutamide, initiating Phase 2 dose optimization, and chose a Phase 3 monotherapy dose for enozertinib. Multiple clinical data readouts are expected across 1Q and 2H 2026, and a global Phase 3 registrational trial in mCRPC is slated to begin in the first half of 2026.